Healthcare Sep 04, 2020 11:09 AM (GMT+8) · EqualOcean
Changchun BCHT Biotech, the first spin-off company of Shenzhen Stock Exchange-listed firm Changchun High-tech Industry (000661:SZ), announced the semi-annual financials in 2020. The company recorded a revenue of CNY 592 million and net profits of CNY 171 million, 45.44% and 78.51% at YoY growth. The company primarily engages in developing, manufacturing and providing human-use vaccines. The primary revenue growth came from the post-pandemic increase in the demand for the chickenpox vaccine. The company has eyed an IPO on China’s Star Market to exploit seven or eight research pipelines, backed up by CNY 300 million expenditure in R & D.

This text is a result of machine translation.